ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,47
-0,05%
Bitcoin
98 341,63
0,04%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) Actualités

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BPMC
DateHeureSourceTitreSymboleSociété
20/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
19/12/202423h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202414h00PR Newswire (US)Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
07/12/202418h30PR Newswire (US)Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
12/11/202419h44Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BPMCBlueprint Medicines Corporation
30/10/202421h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPMCBlueprint Medicines Corporation
30/10/202412h00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
16/10/202414h00PR Newswire (US)Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024NASDAQ:BPMCBlueprint Medicines Corporation
10/09/202414h00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
01/08/202413h00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/07/202414h00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024NASDAQ:BPMCBlueprint Medicines Corporation
31/05/202400h01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
23/05/202423h05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202422h01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202413h00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202414h00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202414h00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
23/02/202414h00PR Newswire (US)Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
16/02/202422h40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BPMCBlueprint Medicines Corporation
15/02/202423h26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPMCBlueprint Medicines Corporation
15/02/202413h00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
01/02/202414h00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024NASDAQ:BPMCBlueprint Medicines Corporation
08/01/202414h00PR Newswire (US)Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202314h00PR Newswire (US)Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
12/12/202314h05PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
09/12/202318h30PR Newswire (US)Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
28/11/202314h00PR Newswire (US)Blueprint Medicines to Present at JMP Securities Hematology and Oncology SummitNASDAQ:BPMCBlueprint Medicines Corporation
10/11/202314h00PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
26/10/202313h00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

Dernières Valeurs Consultées

COIN
SOLUSD
Solana
EU
ORA
Orange
EU
EN
Bouygues
EU
BNP
BNP Paribas
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
USI
USTECH100
US Tech 100
EU
VK
Vallourec
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
SPI
SP500
S&P 500
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés